Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci
Open Access
- 1 June 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 45 (6) , 771-775
- https://doi.org/10.1093/jac/45.6.771
Abstract
Laboratory-derived fluoroquinolone-resistant mutants were obtained by serial passage of Streptococcus sanguis and Streptococcus anginosus isolates on agar containing increasing concentrations of old and new fluoroquinolones, ofloxacin and DU-6859a, respectively. Sequencing of an S. sanguis isolate exposed to DU-6859a showed that resistance was associated with two mutations in the quinolone resistance determining region (QRDR) of the gyrA gene (Ser83→Phe; Glu87→Lys), and with a mutation in the parC gene (Ser79→Ile). However, different mutations in the gyrA gene (Ser83→Tyr) and parC gene (Ser79→Phe) were found in a S. sanguis isolate exposed to ofloxacin. A fluoroquinolone-resistant isolate, QR-95101, from a dental infection, had a single mutation in the gyrA gene (Ser83→Phe) and in the parC gene (Ser79→Phe). Two fluoroquinolone-resistant mutants, QS-701OFm and QS-701DUm, were obtained from S. anginosus QS-701, by exposure to ofloxacin and DU-6859a, respectively. These mutants showed a common substitution at codon 83 (Ser→Phe) in the gyrA gene but had different substitutions at codon 87 (QS-701OFm, Glu→Gln; QS-701DUm, Glu→Lys). They also had different substitutions at codons 79 and 135 in the parC gene (QS-701OFm, Ser79→Leu but no change at Glu135; QS-701DUm, Ser79→Ile and Glu135→Gln). The resistance levels of the DU-6859a-selected resistant S. sanguis mutant QS-951DUm to DU-6859a, ofloxacin, ciprofloxacin and norfloxacin were higher than those of the ofloxacin-selected resistant mutant QS-951OFm. However, ampicillin susceptibilities of these mutants were not different from the parental strains. In S. anginosus, the DU-6859a-selected fluoroquinolone-resistant mutant QS-701DUm was resistant to all the fluoroquinolones tested, while the ofloxacin-selected mutant QS-701OFm was resistant to three fluoroquinolones, but not DU-6859a. The results indicate that different fluoroquinolones select distinct mutations in the QRDR of the gyrA and parC genes in oral streptococci. The gyrA or parC mutation in oral streptococci may determine the levels of fluoroquinolone resistance.Keywords
This publication has 8 references indexed in Scilit:
- DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1998
- Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1995
- Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- New quinolones and gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1994
- Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolatesAntimicrobial Agents and Chemotherapy, 1992
- Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteinsJournal of Bacteriology, 1992
- In vitro activity of sparfloxacin compared with those of five other quinolonesAntimicrobial Agents and Chemotherapy, 1992
- Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984